vs
Apellis Pharmaceuticals, Inc.（APLS）与Priority Technology Holdings, Inc.（PRTH）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$247.1M vs $199.9M），Priority Technology Holdings, Inc.净利率更高（3.6% vs -29.5%，领先33.1%），Priority Technology Holdings, Inc.同比增速更快（8.8% vs -5.9%），Priority Technology Holdings, Inc.自由现金流更多（$30.9M vs $-14.3M），过去两年Priority Technology Holdings, Inc.的营收复合增速更高（9.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
APLS vs PRTH — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $247.1M |
| 净利润 | $-59.0M | $8.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 13.6% |
| 净利率 | -29.5% | 3.6% |
| 营收同比 | -5.9% | 8.8% |
| 净利润同比 | -62.2% | 23.9% |
| 每股收益（稀释后） | $-0.40 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $247.1M | ||
| Q3 25 | $458.6M | $241.4M | ||
| Q2 25 | $178.5M | $239.8M | ||
| Q1 25 | $166.8M | $224.6M | ||
| Q4 24 | $212.5M | $227.1M | ||
| Q3 24 | $196.8M | $227.0M | ||
| Q2 24 | $199.7M | $219.9M | ||
| Q1 24 | $172.3M | $205.7M |
| Q4 25 | $-59.0M | $8.9M | ||
| Q3 25 | $215.7M | $27.6M | ||
| Q2 25 | $-42.2M | $10.9M | ||
| Q1 25 | $-92.2M | $8.3M | ||
| Q4 24 | $-36.4M | $7.2M | ||
| Q3 24 | $-57.4M | $10.6M | ||
| Q2 24 | $-37.7M | $994.0K | ||
| Q1 24 | $-66.4M | $5.2M |
| Q4 25 | -25.6% | 13.6% | ||
| Q3 25 | 48.7% | 15.6% | ||
| Q2 25 | -18.6% | 15.6% | ||
| Q1 25 | -50.0% | 14.5% | ||
| Q4 24 | -12.3% | 15.0% | ||
| Q3 24 | -24.0% | 16.8% | ||
| Q2 24 | -14.7% | 15.1% | ||
| Q1 24 | -36.0% | 13.6% |
| Q4 25 | -29.5% | 3.6% | ||
| Q3 25 | 47.0% | 11.4% | ||
| Q2 25 | -23.6% | 4.5% | ||
| Q1 25 | -55.3% | 3.7% | ||
| Q4 24 | -17.1% | 3.2% | ||
| Q3 24 | -29.2% | 4.7% | ||
| Q2 24 | -18.9% | 0.5% | ||
| Q1 24 | -38.5% | 2.5% |
| Q4 25 | $-0.40 | $0.10 | ||
| Q3 25 | $1.67 | $0.34 | ||
| Q2 25 | $-0.33 | $0.14 | ||
| Q1 25 | $-0.74 | $0.10 | ||
| Q4 24 | $-0.30 | $-0.05 | ||
| Q3 24 | $-0.46 | $0.07 | ||
| Q2 24 | $-0.30 | $-0.23 | ||
| Q1 24 | $-0.54 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $77.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $370.1M | $-100.4M |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $77.2M | ||
| Q3 25 | $479.2M | $57.0M | ||
| Q2 25 | $370.0M | $50.6M | ||
| Q1 25 | $358.4M | $47.6M | ||
| Q4 24 | $411.3M | $58.6M | ||
| Q3 24 | $396.9M | $41.1M | ||
| Q2 24 | $360.1M | $34.6M | ||
| Q1 24 | $325.9M | $34.3M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $997.5M | ||
| Q2 25 | — | $917.0M | ||
| Q1 25 | — | $918.9M | ||
| Q4 24 | — | $920.9M | ||
| Q3 24 | — | $808.1M | ||
| Q2 24 | — | $809.0M | ||
| Q1 24 | $93.1M | $631.4M |
| Q4 25 | $370.1M | $-100.4M | ||
| Q3 25 | $401.2M | $-110.3M | ||
| Q2 25 | $156.3M | $-146.1M | ||
| Q1 25 | $164.2M | $-158.3M | ||
| Q4 24 | $228.5M | $-166.8M | ||
| Q3 24 | $237.1M | $-165.8M | ||
| Q2 24 | $264.3M | $-172.1M | ||
| Q1 24 | $266.7M | $-159.9M |
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $1.8B | ||
| Q3 24 | $901.9M | $1.8B | ||
| Q2 24 | $904.5M | $1.7B | ||
| Q1 24 | $831.9M | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $36.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $30.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 12.5% |
| 资本支出强度资本支出/营收 | 0.1% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 4.12× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $75.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $36.8M | ||
| Q3 25 | $108.5M | $36.1M | ||
| Q2 25 | $4.4M | $17.1M | ||
| Q1 25 | $-53.4M | $10.0M | ||
| Q4 24 | $19.4M | $23.8M | ||
| Q3 24 | $34.1M | $19.8M | ||
| Q2 24 | $-8.3M | $28.7M | ||
| Q1 24 | $-133.0M | $13.3M |
| Q4 25 | $-14.3M | $30.9M | ||
| Q3 25 | $108.3M | $30.1M | ||
| Q2 25 | $4.4M | $9.2M | ||
| Q1 25 | $-53.4M | $4.9M | ||
| Q4 24 | $19.3M | $19.1M | ||
| Q3 24 | — | $14.5M | ||
| Q2 24 | $-8.4M | $23.6M | ||
| Q1 24 | $-133.3M | $6.7M |
| Q4 25 | -7.1% | 12.5% | ||
| Q3 25 | 23.6% | 12.5% | ||
| Q2 25 | 2.5% | 3.8% | ||
| Q1 25 | -32.0% | 2.2% | ||
| Q4 24 | 9.1% | 8.4% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | -4.2% | 10.7% | ||
| Q1 24 | -77.3% | 3.3% |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.0% | 3.3% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.0% | 2.0% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 2.3% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | 0.50× | 1.31× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 3.29× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 28.87× | ||
| Q1 24 | — | 2.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRTH
暂无分部数据
